Market Overview

Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design

Related RPRX
FDA Confirms Endpoints of Androxal Study
Repros' Q1 Loss In Line with Expectations - Analyst Blog

Repros Therapeutics Inc.^® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.

Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.

Posted-In: News FDA

 

Most Popular

Related Articles (RPRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free